Biogen and Denali’s BIIB122 Parkinson’s Trial Completion Sets Up Key Catalyst for Investors
Denali Therapeutics (DNLI), Biogen Inc. (BIIB) announced an update on their ongoing clinical study.
Memorial Day Sale – Claim 70% Off TipRanks
- Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis.
- Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter
The Phase 2b study called “A Study to Learn About the Safety of BIIB122 Tablets and Whether They Can Slow the Worsening of Early-Stage Parkinson’s Disease in Adults Between the Ages of 30 and 80” tests whether Biogen and Denali’s oral drug BIIB122 can slow early Parkinson’s disease. It focuses on safety and how fast symptoms worsen, an area with high unmet need and strong commercial potential.
BIIB122, also known as DNL151, is an oral tablet designed to target a key pathway linked to Parkinson’s progression. The trial compares daily BIIB122 tablets with a look‑alike placebo to see if the drug can slow disease worsening while remaining safe for long‑term use.
The study is an interventional Phase 2 trial where adults with early Parkinson’s are randomly assigned to BIIB122 or placebo. It is double‑blind, meaning patients, doctors, and assessors do not know who gets the active drug, and the main goal is to test treatment benefit rather than diagnosis or prevention.
Patients take a tablet once a day for roughly one to three years, with at least one year of participation and up to 29 clinic visits. The main outcome is how long it takes for symptoms to get worse on standard Parkinson’s rating scales, which helps show if BIIB122 slows decline in daily function.
The trial started after first submission on 4 April 2022 and has now reached “Completed” status, which means treatment and follow‑up are finished. The record was last updated on 28 May 2026, but results are not yet posted, so investors are still waiting for the key efficacy readout that will guide the drug’s future.
For Biogen (BIIB), a positive outcome could open a new growth pillar beyond multiple sclerosis and Alzheimer’s, supporting a higher multiple on future earnings. Denali Therapeutics (DNLI) could see an outsized move because BIIB122 is a core asset in its pipeline, and success would validate its broader neurodegeneration strategy.
If data show a clear benefit on symptom progression with an acceptable safety profile, both stocks could gain as investors price in a likely Phase 3 program and potential partnership milestones. Weak or mixed data could pressure shares, especially for DNLI, and push investors toward other Parkinson’s players such as U.S. and European firms advancing gene therapies and other novel approaches.
With the study now completed and the listing recently updated on ClinicalTrials.gov, the market will focus on the timing and strength of the upcoming data release. The study status is updated and ongoing from a disclosure standpoint, with further details available on the ClinicalTrials portal.
To learn more about DNLI’s potential, visit the Denali Therapeutics drug pipeline page.
